Literature DB >> 7611822

Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia.

A Schneider1, T Grubert, R Kirchmayr, D Wagner, U Papendick, G Schlunck.   

Abstract

OBJECTIVE: Dose dependent response of cervical intraepithelial neoplasia (CIN) to topically administered interferon (IFN) gamma was assessed and compared with conventional laser therapy. PATIENT AND METHODS: 33 women were included in a randomized phase II trial which was double blinded for IFN dosages. Twenty-four patients received IFN gamma-1 beta gel and a control group of nine patients was treated with laser surgery. 18 patients had smears suggesting CIN II and 15 patients had smears suggesting CIN III. The response was assessed 6 months after starting of IFN gamma-1 beta treatment or having laser surgery.
RESULTS: Topical IFN gamma-1 beta treatment gave a cure rate of 42% independent of IFN dosage as compared to an 89% cure rate with laser therapy (P = 0.02). Patients with CIN II responded better compared with patients with CIN III. Current smokers showed a significantly lower cure rate whereas use of oral contraceptives (OC) did not influence response. High viral load with high risk types of human papillomaviruses (HPV) was associated with a better response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7611822     DOI: 10.1007/BF00634712

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  42 in total

1.  Smoking and cervical intraepithelial neoplasia: nicotine and cotinine in serum and cervical mucus in smokers and nonsmokers.

Authors:  D Hellberg; S Nilsson; N J Haley; D Hoffman; E Wynder
Journal:  Am J Obstet Gynecol       Date:  1988-04       Impact factor: 8.661

2.  Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change?

Authors:  S E Barton; P H Maddox; D Jenkins; R Edwards; J Cuzick; A Singer
Journal:  Lancet       Date:  1988-09-17       Impact factor: 79.321

3.  Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial.

Authors:  M Yliskoski; K Syrjänen; S Syrjänen; S Saarikoski; A Nethersell
Journal:  Gynecol Oncol       Date:  1991-10       Impact factor: 5.482

Review 4.  Interferon-gamma, prototype of the proinflammatory cytokines--importance in activation, suppression, and maintenance of the immune response.

Authors:  P F Halloran
Journal:  Transplant Proc       Date:  1993-04       Impact factor: 1.066

5.  Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with viral cytopathic effects. A pilot study.

Authors:  G De Palo; B Stefanon; F Rilke; S Pilotti; M Ghione
Journal:  J Reprod Med       Date:  1985-05       Impact factor: 0.142

6.  Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives.

Authors:  A Pater; M Bayatpour; M M Pater
Journal:  Am J Obstet Gynecol       Date:  1990-04       Impact factor: 8.661

7.  No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia.

Authors:  L Frost; K Skajaa; L E Hvidman; S J Fay; P M Larsen
Journal:  Br J Obstet Gynaecol       Date:  1990-07

8.  Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears.

Authors:  A Schneider; T Kirchhoff; G Meinhardt; L Gissmann
Journal:  Obstet Gynecol       Date:  1992-05       Impact factor: 7.661

9.  Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization.

Authors:  M Dürst; D Glitz; A Schneider; H zur Hausen
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

10.  Treatment of dysplasia of the cervical epithelium with an interferon gel.

Authors:  B R Møller; P Johannesen; K Osther; U Ulmsteen; J Hastrup; K Berg
Journal:  Obstet Gynecol       Date:  1983-11       Impact factor: 7.661

View more
  1 in total

Review 1.  Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.

Authors:  S C Piscitelli; W G Reiss; W D Figg; W P Petros
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.